Exploring the ElectroRetinoGraphy as a biomarker for predicting and monitoring therapeutic response to antidepressants in major depressive disorder: study protocol for the MESANTIDEP trial.

Fiche publication

Date publication

avril 2025

Journal

Frontiers in psychiatry

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ALBUISSON Eliane

Tous les auteurs :
de Deus M, Petit C, Moulard M, Cosker E, Mellouki Bendimred N, Albuisson É, Maruani J, Geoffroy PA, Schwitzer T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40352365

Résumé

Major depressive disorder (MDD) is a frequent and highly debilitating condition for which current antidepressant treatments show limited effectiveness. In addition, their implementation requires one or more trial-and-error processes, which involves months of untreated illness. Achieving faster efficacy by identifying the most adapted treatment for each patient as the first line treatment could significantly reduce MDD-related morbidity and mortality while enhancing patients' quality of life. To achieve this goal, there is a need to identify markers for predicting and monitoring therapeutic response to antidepressants.